menu
    • menu

    Company profile for ChemDiv

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ChemDiv, a fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA, has been a pioneer in discovery libraries since 1991. Its first diverse heterocyclic compounds collection was compiled from academic lab sources from all over the world, and ChemDiv subsequently successfully launched its own large-scale library synthesis program.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ChemDivUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12760 High Bluff Drive, Suite 370 San Diego, CA 92130 USA
    Telephone
    Telephone
    +1 858-794-4860
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.chemdiv.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ChemDiv Develops Reversible Pan-EGFR Inhibitors for Lung Cancer
    ChemDiv Develops Reversible Pan-EGFR Inhibitors for Lung Cancer

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdivs-discovery-platform-enables-differentiated-reversible-panegfr-kinase-inhibitors-for-gfrmutant-lung-cancer-302599522.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    ChemDiv Extends CMC Collaboration For Ratutrelvir In Ph 2 Trial
    ChemDiv Extends CMC Collaboration For Ratutrelvir In Ph 2 Trial

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-extends-cmc-services-collaboration-for-ratutrelvir-a-potential-best-in-class-covid-19-therapeutic-advancing-in-phase-2-clinical-trials-302599828.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    ChemDiv Continues R&D Support for Clywedog After Merger
    ChemDiv Continues R&D Support for Clywedog After Merger

    24 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-continues-rd-services-support-for-clywedog-therapeutics-following-merger-with-barinthus-therapeutics-302593839.html

    PR NEWSWIRE
    24 Oct 2025
    Share Share
    Chemdiv Extends Partnership With Mondego Bio On PTPN2 Program
    Chemdiv Extends Partnership With Mondego Bio On PTPN2 Program

    24 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-extends-discovery-and-early-development-partnership-with-mondego-bio-on-best-in-class-ptpn2-immuno-oncology-program-302593824.html

    PR NEWSWIRE
    24 Oct 2025
    Share Share
    ChemDiv to Participate in the EF Hutton Annual Global Conference, May 15, 2024
    ChemDiv to Participate in the EF Hutton Annual Global Conference, May 15, 2024

    13 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-to-participate-in-the-ef-hutton-annual-global-conference-may-15-2024-302143637.html

    PR NEWSWIRE
    13 May 2024
    Share Share
    ChemDiv Marks a Milestone as Orionis' Novel Immunotherapy Enters Ph I Trials
    ChemDiv Marks a Milestone as Orionis' Novel Immunotherapy Enters Ph I Trials

    03 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-marks-a-milestone-as-orionis-biosciences-novel-immunotherapy-enters-phase-i-clinical-trials-302025515.html

    PR NEWSWIRE
    03 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search